<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">107945</article-id><article-id pub-id-type="doi">10.7554/eLife.107945</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Cardiac Repair</subject></subj-group></article-categories><title-group><article-title>Aiming for spatial and temporal control of gene expression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Igor Travisano</surname><given-names>Stanislao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6453-0367</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Stanislao Igor Travisano</bold> is in The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, United States</p></bio></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lien</surname><given-names>Ching-Ling</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5100-9780</contrib-id><email>clien@chla.usc.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Ching-Ling Lien</bold> is in The Saban Research Institute of Children's Hospital Los Angeles and the Departments of Surgery, Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, United States</p></bio></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00412ts95</institution-id><institution>The Saban Research Institute of Children's Hospital Los Angeles</institution></institution-wrap><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03taz7m60</institution-id><institution>The Saban Research Institute of Children's Hospital Los Angeles, Departments of Surgery, Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California</institution></institution-wrap><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>07</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e107945</elocation-id><permissions><copyright-statement>© 2025, Igor Travisano and Lien</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Igor Travisano and Lien</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-107945-v1.pdf"/><related-article related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.7554/eLife.107148" id="ra1"/><abstract><p>Bioluminescent imaging is helping researchers better understand the effectiveness of tissue regeneration enhancers delivered to injured heart tissue by different adeno-associated virus vectors.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>bioluminescent imaging</kwd><kwd>gene therapy</kwd><kwd>tissue regeneration enhancers</kwd><kwd>adeno-associated virus</kwd><kwd>myocardial infarction</kwd><kwd>cardiac</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Bioluminescent imaging is helping researchers better understand the effectiveness of tissue regeneration enhancers delivered to injured heart tissue by different adeno-associated virus vectors.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Template</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Wolfson DW, Hull JA, Li Y, Gonzalez TJ, Jayaram MD, Devlin GW, Cigliola V, Oonk KA, Rosales A, Bursac N, Asokan A, Poss KD. 2025. Spatial and longitudinal tracking of enhancer-AAV vectors that target transgene expression to injured mouse myocardium. <italic>eLife</italic> <bold>14</bold>:RP107148. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.107148">10.7554/eLife.107148</ext-link>.</p></boxed-text><p>Gene therapy – where functional copies of genes are delivered to certain cells in a patient – is becoming a reality for patients with cancer and a range of genetic disorders, including Duchenne muscular dystrophy and sickle cell disease. Such therapies are often delivered via an adeno-associated virus, a generally non-toxic viral vector that has shown promise as a delivery system in various gene therapy trials (<xref ref-type="bibr" rid="bib6">Kuzmin et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Wang et al., 2019</xref>).</p><p>This delivery system also has the potential to drive the expression of repair genes in injured tissues by delivering short sequences of DNA called TREEs (which is short for tissue regeneration enhancer elements). TREEs are activated by injury signals and can drive the expression of regenerative genes in damaged and regenerating tissues. Although TREEs were discovered in zebrafish, which have the capacity to regenerate damaged tissue, they can also trigger the expression of repair genes in other species. In particular, three enhancers that direct gene expression during heart regeneration in zebrafish (<xref ref-type="bibr" rid="bib4">Kang et al., 2016</xref>; <xref ref-type="bibr" rid="bib1">Goldman et al., 2017</xref>) can, when delivered using adeno-associated viruses, improve heart repair in both mice and pigs (<xref ref-type="bibr" rid="bib10">Yan et al., 2023</xref>).</p><p>However, translating this strategy into clinical use is challenging, with a major concern being the risk of off-target effects, particularly when using genes that stimulate cell proliferation. Now, in eLife, Aravind Asokan, Kenneth Poss and colleagues – including David Wolfson as first author – report how different adeno-associated virus capsids and TREEs affect gene expression in a mouse model of myocardial infarction (<xref ref-type="bibr" rid="bib9">Wolfson et al., 2025</xref>). The team – who are based at Duke University, Vanderbilt University, the Morgridge Institute for Research, and the University of Wisconsin-Madison – used bioluminescent imaging to track the expression of TREE-activated reporter genes in both time and space, and to explore the influence of the different delivery systems.</p><p>The expression patterns of two TREEs associated with heart injury (REN and 2ankrd1aEN) were analysed using bioluminescent imaging following delivery via AAV9 – a widely used adeno-associated virus variant known for driving high gene expression in the heart, but with notable off-target effects in the liver (<xref ref-type="bibr" rid="bib7">Prasad et al., 2011</xref>). Wolfson et al. also delivered the same TREEs using AAV.cc84 – an engineered AAV9 variant specifically designed to reduce off-target effects in the liver (<xref ref-type="bibr" rid="bib3">Gonzalez et al., 2023</xref>; <xref ref-type="bibr" rid="bib2">Gonzalez et al., 2022</xref>). This revealed that AAV.cc84 achieved effective cardiac delivery with markedly reduced off-target expression compared to AAV9.</p><p>While AAV9 targets heart muscle cells well, it tends to deliver genes mostly to cells bordering the injury, rather than those in the damaged area (<xref ref-type="bibr" rid="bib5">Konkalmatt et al., 2012</xref>). To overcome this limitation, Wolfson et al. screened adeno-associated virus capsid libraries to find variants that deliver TREE- directed reporters to the heart muscle cells within the injury site while scar tissue is forming. A new capsid variant – AAV.IR41 – showed an enhanced ability to deliver TREE-reporters to cells within the damaged area.</p><p>The findings of Wolfson et al. highlight the potential of combining injury-induced TREEs with specially designed viral carriers to control gene expression at specific locations and times after tissue injury to promote regeneration. Despite these advancements, several challenges remain. While in vivo bioluminescence imaging is powerful, it is constrained by tissue depth limitations, restricting its use in larger animal models and therefore necessitating complementary imaging or molecular approaches to validate findings across species.</p><p>Although the off-target expression observed in areas such as the liver, neck and abdomen can be partially minimised by capsid design, a deeper understanding of how different gene elements interact, as well as why different viral vectors are specific to certain tissues, is required. Reporter genes delivered by AAV.IR41 showed overall much stronger expression than AAV9 and therefore off-target effects could be more widespread. Combining features of AAV.cc84 and AAV.IR41 could represent an exciting opportunity to further minimize such off-target effects.</p><p>Furthermore, the efficacy of AAV.IR41 could be better understood by comparing how it works after different types of heart injury: ischemia-reperfusion (where the blood flow is restored after the blockage) and injuries where the blockage is permanent. Does the efficacy of AAV.IR41 improve when blood flow is restored by reperfusion? Lastly, it will be interesting to determine whether TREE-driven gene expression returns to baseline once heart regeneration is complete, which would suggest that TREEs are only active during injury and become inactive after recovery.</p><p>Looking forward, further optimization of TREE-directed gene delivery via adeno-associate virus vectors could pave the way for more therapeutic applications. Translating such strategies into larger animal models and, ultimately, clinical settings will require scalability, new imaging methods, and robust safety assessments. The work of Wolfson et al. establishes a critical platform for the rational design of enhancer-adeno-associated virus combinations tailored to the tissue regeneration, and lays the groundwork for a new generation of gene therapies aimed at harnessing the body’s intrinsic repair mechanisms.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>JA</given-names></name><name><surname>Kuzu</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Karasik</surname><given-names>J</given-names></name><name><surname>Gemberling</surname><given-names>M</given-names></name><name><surname>Foglia</surname><given-names>MJ</given-names></name><name><surname>Karra</surname><given-names>R</given-names></name><name><surname>Dickson</surname><given-names>AL</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Tolstorukov</surname><given-names>MY</given-names></name><name><surname>Poss</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Resolving heart regeneration by replacement histone profiling</article-title><source>Developmental Cell</source><volume>40</volume><fpage>392</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2017.01.013</pub-id><pub-id pub-id-type="pmid">28245924</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>TJ</given-names></name><name><surname>Simon</surname><given-names>KE</given-names></name><name><surname>Blondel</surname><given-names>LO</given-names></name><name><surname>Fanous</surname><given-names>MM</given-names></name><name><surname>Roger</surname><given-names>AL</given-names></name><name><surname>Maysonet</surname><given-names>MS</given-names></name><name><surname>Devlin</surname><given-names>GW</given-names></name><name><surname>Smith</surname><given-names>TJ</given-names></name><name><surname>Oh</surname><given-names>DK</given-names></name><name><surname>Havlik</surname><given-names>LP</given-names></name><name><surname>Castellanos Rivera</surname><given-names>RM</given-names></name><name><surname>Piedrahita</surname><given-names>JA</given-names></name><name><surname>ElMallah</surname><given-names>MK</given-names></name><name><surname>Gersbach</surname><given-names>CA</given-names></name><name><surname>Asokan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>5947</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-33745-4</pub-id><pub-id pub-id-type="pmid">36210364</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>TJ</given-names></name><name><surname>Mitchell-Dick</surname><given-names>A</given-names></name><name><surname>Blondel</surname><given-names>LO</given-names></name><name><surname>Fanous</surname><given-names>MM</given-names></name><name><surname>Hull</surname><given-names>JA</given-names></name><name><surname>Oh</surname><given-names>DK</given-names></name><name><surname>Moller-Tank</surname><given-names>S</given-names></name><name><surname>Castellanos Rivera</surname><given-names>RM</given-names></name><name><surname>Piedrahita</surname><given-names>JA</given-names></name><name><surname>Asokan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Structure-guided AAV capsid evolution strategies for enhanced CNS gene delivery</article-title><source>Nature Protocols</source><volume>18</volume><fpage>3413</fpage><lpage>3459</lpage><pub-id pub-id-type="doi">10.1038/s41596-023-00875-y</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Karra</surname><given-names>R</given-names></name><name><surname>Dickson</surname><given-names>AL</given-names></name><name><surname>Tornini</surname><given-names>VA</given-names></name><name><surname>Nachtrab</surname><given-names>G</given-names></name><name><surname>Gemberling</surname><given-names>M</given-names></name><name><surname>Goldman</surname><given-names>JA</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name><name><surname>Poss</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Modulation of tissue repair by regeneration enhancer elements</article-title><source>Nature</source><volume>532</volume><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1038/nature17644</pub-id><pub-id pub-id-type="pmid">27049946</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konkalmatt</surname><given-names>PR</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Piras</surname><given-names>BA</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>O’Connor</surname><given-names>DM</given-names></name><name><surname>Beyers</surname><given-names>RJ</given-names></name><name><surname>Epstein</surname><given-names>FH</given-names></name><name><surname>Annex</surname><given-names>BH</given-names></name><name><surname>Hossack</surname><given-names>JA</given-names></name><name><surname>French</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling</article-title><source>Journal of Gene Medicine</source><volume>14</volume><fpage>609</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1002/jgm.2673</pub-id><pub-id pub-id-type="pmid">23065925</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuzmin</surname><given-names>DA</given-names></name><name><surname>Shutova</surname><given-names>MV</given-names></name><name><surname>Johnston</surname><given-names>NR</given-names></name><name><surname>Smith</surname><given-names>OP</given-names></name><name><surname>Fedorin</surname><given-names>VV</given-names></name><name><surname>Kukushkin</surname><given-names>YS</given-names></name><name><surname>van der Loo</surname><given-names>JCM</given-names></name><name><surname>Johnstone</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The clinical landscape for AAV gene therapies</article-title><source>Nature Reviews Drug Discovery</source><volume>20</volume><fpage>173</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1038/d41573-021-00017-7</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>KMR</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Acton</surname><given-names>ST</given-names></name><name><surname>French</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Robust cardiomyocyte-specific gene expression following systemic injection of AAV: In vivo gene delivery follows a Poisson distribution</article-title><source>Gene Therapy</source><volume>18</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/gt.2010.105</pub-id><pub-id pub-id-type="pmid">20703310</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Tai</surname><given-names>PWL</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Adeno-associated virus vector as a platform for gene therapy delivery</article-title><source>Nature Reviews Drug Discovery</source><volume>18</volume><fpage>358</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0012-9</pub-id><pub-id pub-id-type="pmid">30710128</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfson</surname><given-names>DW</given-names></name><name><surname>Hull</surname><given-names>JA</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Gonzalez</surname><given-names>TJ</given-names></name><name><surname>Jayaram</surname><given-names>MD</given-names></name><name><surname>Devlin</surname><given-names>GW</given-names></name><name><surname>Cigliola</surname><given-names>V</given-names></name><name><surname>Oonk</surname><given-names>KA</given-names></name><name><surname>Rosales</surname><given-names>A</given-names></name><name><surname>Bursac</surname><given-names>N</given-names></name><name><surname>Asokan</surname><given-names>A</given-names></name><name><surname>Poss</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Spatial and longitudinal tracking of enhancer-AAV vectors that target transgene expression to injured mouse myocardium</article-title><source>eLife</source><volume>14</volume><elocation-id>RP107148</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.107148</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Cigliola</surname><given-names>V</given-names></name><name><surname>Oonk</surname><given-names>KA</given-names></name><name><surname>Petrover</surname><given-names>Z</given-names></name><name><surname>DeLuca</surname><given-names>S</given-names></name><name><surname>Wolfson</surname><given-names>DW</given-names></name><name><surname>Vekstein</surname><given-names>A</given-names></name><name><surname>Mendiola</surname><given-names>MA</given-names></name><name><surname>Devlin</surname><given-names>G</given-names></name><name><surname>Bishawi</surname><given-names>M</given-names></name><name><surname>Gemberling</surname><given-names>MP</given-names></name><name><surname>Sinha</surname><given-names>T</given-names></name><name><surname>Sargent</surname><given-names>MA</given-names></name><name><surname>York</surname><given-names>AJ</given-names></name><name><surname>Shakked</surname><given-names>A</given-names></name><name><surname>DeBenedittis</surname><given-names>P</given-names></name><name><surname>Wendell</surname><given-names>DC</given-names></name><name><surname>Ou</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Goldman</surname><given-names>JA</given-names></name><name><surname>Baht</surname><given-names>GS</given-names></name><name><surname>Karra</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>AR</given-names></name><name><surname>Bowles</surname><given-names>DE</given-names></name><name><surname>Asokan</surname><given-names>A</given-names></name><name><surname>Tzahor</surname><given-names>E</given-names></name><name><surname>Gersbach</surname><given-names>CA</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name><name><surname>Bursac</surname><given-names>N</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name><name><surname>Poss</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>An enhancer-based gene-therapy strategy for spatiotemporal control of cargoes during tissue repair</article-title><source>Cell Stem Cell</source><volume>30</volume><fpage>96</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2022.11.012</pub-id><pub-id pub-id-type="pmid">36516837</pub-id></element-citation></ref></ref-list></back></article>